A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results
Conclusion
Both S-1 and capecitabine were active and tolerable for elderly MGC patients. The CYP2A6 genotyping might guide treatment selection.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | Study | Toxicology | Xeloda